APA

Bonecker S., Carvalho G., Dobbin J., Zalcberg I. & Schaffel R. (20200501). Early molecular response ≤1% has strong prognostic impact for CML patients that switch to second-line therapy with BCR-ABL1 ≤10% and no major molecular response. : British journal of haematology.

Chicago

Bonecker Simone, Carvalho Gabriela, Dobbin Jane, Zalcberg Ilana and Schaffel Rony. 20200501. Early molecular response ≤1% has strong prognostic impact for CML patients that switch to second-line therapy with BCR-ABL1 ≤10% and no major molecular response. : British journal of haematology.

Harvard

Bonecker S., Carvalho G., Dobbin J., Zalcberg I. and Schaffel R. (20200501). Early molecular response ≤1% has strong prognostic impact for CML patients that switch to second-line therapy with BCR-ABL1 ≤10% and no major molecular response. : British journal of haematology.

MLA

Bonecker Simone, Carvalho Gabriela, Dobbin Jane, Zalcberg Ilana and Schaffel Rony. Early molecular response ≤1% has strong prognostic impact for CML patients that switch to second-line therapy with BCR-ABL1 ≤10% and no major molecular response. : British journal of haematology. 20200501.